ABSTRACT Recent studies suggest that platelet activation and subsequent thromboxane (TX) A2 release play important roles in certain coronary syndromes. To further test this possibility, we examined the ability of a selective TXA2-synthetase inhibitor, dazoxiben , to abolish cyclic flow reductions (CFRs) that occur in experimentally stenosed canine coronary arteries. CFRs, which are characterized by progressive declines in coronary blood flow and interrupted by sudden and usually spontaneous restorations of flow, were produced by placing hard plastic cylindrical constrictors (5 mm long x 4.5 mm outer diameter) on the proximal left anterior descending or circumflex coronary artery in open-chest, anesthetized dogs. Coronary blood flow was measured with pulsed Doppler flow probes placed proximal to the constrictors and regional myocardial blood flow with 15 ,um radiolabeled microspheres. CFRs were observed for 1 hr, during which coronary blood flow was monitored continuously. Regional myocardial blood flow was measured before constriction, when coronary blood flow appeared to be at its nadir, and after spontaneous restorations of flow. After 1 hr dazoxiben (2.5 mg/kg iv) or an equal volume of saline was given and coronary blood flow was monitored for another hour. Dazoxiben abolished CFRs completely in 18 of 28 dogs and significantly reduced their frequency in the dogs receiving the drug (10.1 ± 0.8 vs 3.2 ± 1.0 per hour [±SE]; p < .001, n = 28). The frequency and magnitude of variations in cyclic blood flow were unchanged after saline (8.8 ± 0.8 vs 9.0 ± 1.0 per hour; p = NS, n = 13). The lowest levels of coronary blood flow before and after dazoxiben were 8.6 ±-2.2% and 48.8 ± 5.4% of control, respectively (p < .001, n = 28), whereas this parameter remained unchanged after saline (18.7 ± 5.7% vs 13.4 ± 4.1%, respectively; n = 13). The levels of TXB2 and 6-keto-prostaglandin (PG) F Ia (stable breakdown products of TXA2 and prostacyclin, respectively) were measured in blood collected from aortic and distal coronary arterial catheters before coronary constriction (control), during CFRs, and after administration of dazoxiben. TXB2 levels measured distal to the stenosis were increased fivefold during CFRs (352 ± 126 vs 71 + 18 pg/ml plasma; p < .03) and were reduced to preconstriction (control) levels by dazoxiben (57 ± 12 pg/ml). Aortic TXB2 levels almost doubled with CFRs and also returned to control levels after dazoxiben. Distal coronary arterial 6-keto-PGF levels also increased significantly during CRFs (133 + 22 to 344 ± 41 pg/ml plasma), but remained elevated (343 ± 82 pg/ml plasma) after dazoxiben treatment. Systemically administered dazoxiben (2.5 mg/kg iv) suppressed arachidonic acid-induced production of TXB2 (but not PGE2) by platelets. Dazoxiben (1 gM) did not affect PGL2 synthesis by canine coronary arterial rings in vitro. Thus, dazoxiben eliminates or markedly attenuates cyclic flow reductions in stenotic canine coronary arteries and selectively inhibits TXA2 synthesis. The data obtained in this study suggest that increases in coronary arterial TXA2 concentration play a role in the genesis of cyclic flow reductions in this experimental model.
ported beneficial effects in myocardial ischemic syndromes have been interpreted as evidence that TXA2 production is more prominent in this setting.9 However, it is unclear whether these agents truly exert a beneficial influence in myocardial ischemic syndromes since they possess the ability to block both PGI2 and TXA2 synthesis. A more desirable approach would be to inhibit TXA2 synthesis selectively, without affecting PGI2 synthesis.
Accordingly, this study was undertaken to evaluate the effects of dazoxiben (UK-37-248), an imidazolecontaining compound that selectively inhibits TX synthetase,'0 on cyclic flow reductions (CFRs) and platelet aggregation in dogs with experimentally stenosed coronary arteries. The preparation used in this study is similar to the one described previously by Folts and his colleagues", 12 and to that used by Aiken et al. 13' 14 It is thought that platelet and red blood cell aggregates form in severely stenotic coronary arteries and then break loose. This phenomenon produces CFRs, which are characterized by progressive declines in flow interrupted by sudden and usually spontaneous restorations of flow. We hypothesized that selective inhibition of TXA2 synthesis with dazoxiben can abolish these CFRs by ifihibiting platelet TXA2 production. Methods Surgical preparation. Mongrel dogs (17 to 27 kg) of either sex were anesthetized with sodium pentobarbital (30 mg/kg iv) and ventilated artificially with room air. Aortic and venous catheters were inserted in each via the common carotid artery and external jugular vein, respectively. A thoracotomy was performed in the fifth left intercostal space and the heart was suspended in a pericardial cradle. A Konigsberg pressure transducer was inserted into the left ventricular apex and another catheter was inserted into the left atrium for injecting tracer microspheres. 15 A segment of the left anterior descending (LAD) or left circumflex (LCX) coronary artery was dissected away from surrounding tissue gently and a pulsed Doppler flow probe (manufactured by Dr. C. J. Hartley, Houston) was placed on the coronary artery proximal to where the constriction would subsequently be positioned. Alto, when possible, a small polyethylene catheter was inserted into the distal end of a diagonal branch of the LAD below the site of constriction, enabling the pressure gradient across the stenosis to be measured. The experimental preparation is illustrated in figure 1. Experimental protocol. After instrumentation, dogs were allowed to stabilize for '/2 hr. Control hemodynamic measurements included those of heart rate, arterial blood pressure, left ventricular dP/dt, and phasic and mean coronary flow, all of which were recorded continuously on a Hewlett-Packard (Model 7758) 8-channel recorder. The Doppler flow probes were calibrated on coronary arteries in a separate group of four dogs. 16 Regional myocardial blood flow was measured with 15 ,um carbonized microspheres labeled with 125J, 46Sc, I13Sn, 5Sr, 95Nb, and 57Co. Microspheres were sonicated and vortexed for several minutes and 1 to 3 million spheres were injected into the left atrium over an 8 to 10 sec period. Starting 10 sec before and continuing for 90 sec after microsphere injection, reference arterial blood was withdrawn from the carotid artery at a conSonar ' Crystals FIGURE 1. Schematic diagram of cardiac preparation for studying CFRs. Stippled area represents area made ischemic by coronary constrictor and intravascular platelet aggregation. Ao = aorta; PA pulmonary artery; RV = right ventricle; LV = left ventricle. stant rate of 7.8 ml/min with a Harvard infusion/withdrawal pump. The order of isotope injection was changed randomly.
After obtaining control measurements, the hyperemic response after a 10 sec total occlusion was measured. Then a hard plastic cylindrical constrictor similar to that described by Folts et al." 12 was placed on the coronary artery 5 to 15 mm distal to the Doppler flow probe. The cyclic flow pattern, which is indicative of platelet aggregation and spontaneous release, was produced after identifying a constrictor of suitable internal diameter that completely (or nearly so) eliminated the hyperemic response after a 10 sec occlusion.'7 Once attained, the cyclic coronary flow pattern was observed for 1 hr during which coronary blood flow was monitored continuously by Doppler flow probe. Regional myocardial blood flow measurements were obtained when coronary blood flow was approximately at its nadir and after a spontaneous restoration of flow. During the hour of observation, the frequency of these CFRs was recorded, as were the zenith and nadir of coronary blood flow.
After 1 hr dazoxiben* (2.5 mg/kg in 20 ml saline) was administered to 28 dogs intravenously over 1 min. Hemodynamic variables and CFRs were monitored continuously for another hour and changes in the pattern of coronary blood flow were compared with those occurring during the first hour. Another group (n = 13 dogs) received an equal volume of saline and was observed for an additional 1 hr period to determine whether spontaneous changes in the cyclic coronary flow pattern occurred in the absence of the drug. To further test the hypothesis that selective reductions in TXA2 production at the site of the stenosis are primarily responsible for abolition of CFRs, the stable endoperoxide analog U46619 was given, intra-atrially or topically (1 to 5 ,ug), in an effort to restore CRFs after their abolition by dazoxiben in seven dogs. To determine maximal decreases in coronary blood flow, regional myocardial blood flow, and distal coronary pressure, the constricted coronary artery was occluded totally at the end of each experiment, and all measurements (including those of regional myocardial blood flow) were repeated within 3 min after occlusion. Next, to delineate the ischemic zone of the left ventricle, 10 ml of 10% *Generously provided by Dr. Pedro Urquilla at Pfizer Pharmaceuticals, Groton, CT.
CIRCULATION
(weight/volume) patent blue violet (Alphazurine) was injected quickly into the left atrium, followed by a 5 ml flush and electrical fibrillation of the heart. Ischemic left ventricular tissue was sampled from that area well within the perimeter of unstained left ventricular myocardium.
Effects of dazoxiben on intravascular TXA2 production in vivo. Blood samples for determination of the intravascular production of TXA2 and PGI2 were taken from the aortic and distal coronary catheters before coronary constriction, during two CFRs (as coronary blood flow was declining before dazoxiben was given), and 10 min after the administration of 2.5 mg/kg dazoxiben. Both catheters were filled with heparin sodium (from beef lung; 1000 units/ml) immediately after placement and after each blood sample was obtained. After discarding blood contained in the void space of each catheter, blood from both aortic and distal coronary arterial catheters was allowed to flow directly into chilled Vacutainer tubes (Becton-Dickinson; 12 ml samples) containing indomethacin (10 ,g ) and heparin (1500 units). TXA2 levels were measured from blood samples obtained when maximal platelet TXA2 production was believed to be occurring, such as during CFRs. Blood was collected from the aortic and distal coronary catheters starting 1 to 2 min before the anticipated restoration of coronary blood flow. To avoid spuriously high TXA2 levels in the aortic samples due to intracatheter clotting, the entire aortic blood sample was collected immediately, while blood flow from the distal coronary catheter was allowed to continue. In some cases, when coronary blood flow approached zero, flow from the distal catheter practically ceased. In these cases, to avoid intracatheter clotting, platelet activation, and spurious TXA2 production, coronary blood flow through the stenosed coronary was restored by lightly tapping the constrictor. During blood collections, the Vacutainer tubes were kept in an ice-water slurry. The third set of blood samples was obtained between 10 to 15 min after dazoxiben administration. In 10 of the dogs the flow rate from the distal coronary arterial catheter was measured by dividing the volume of blood obtained by the collection time (pg/ml plasma x ml/min = pg/ min), which enabled calculations of production to be made. Blood samples were centrifuged (40 C) at 1500 rpm for 10 min, and the plasma was separated and frozen until the batch analyses for TXB2 and 6-keto-PGFIa levels were performed.
Morphologic studies. The LAD of each of five dogs was suture-ligated on both sides of the plastic constrictor at a point in time when a reduction in cyclic blood flow had occurred and blood flow through the vessel was at its nadir. Suture ligation also was performed without plastic constrictors in two control coronary arteries. The segments of arteries were removed and fixed in 10% formalin in phosphate buffer. The segments were dehydrated and embedded in methacrylate in a longitudinal orientation. Longitudinal sections were cut and stained with toluidine blue. The sections were examined and photographed by light microscopy.
Effects of systemically administered dazoxiben on platelet TXA2 production in vitro. To confirm that dazoxiben possesses the ability to inhibit TXA2 production, the production of TXA2 was measured in vitro in platelet-rich plasma prepared from blood drawn from a separate group of five dogs. Three of these dogs were anesthetized with sodium pentobarbital and ventilated artificially. A segment of the LAD was isolated after exposing the heart via a left thoracotomy to reproduce the experimental preparation we used as closely as possible. A 20 min stabilization period was allowed and 18 ml of blood was collected from the antecubital vein of each dog before and 5 and 30 min after the administration of dazoxiben (2.5 mg/kg iv). Two other dogs were lightly restrained in a standing sling. Each blood sample was replaced with an equal volume of saline. The blood samples were quickly, but gently, transferred to plastic tubes containing 2 ml of 3.5% sodium citrate, pH 7.4, and this was followed by two gentle inversions to ensure adequate mixing. Centrifugation at 150 g for 10 min resulted in a plasma suspension of platelets. After removal of the platelet-rich plasma, the remaining blood was centrifuged at 1500 g for 10 min to obtain platelet-poor plasma.
Prostaglandin measurements. TXB2, the stable breakdown product of TXA2, 6-keto-PGF,l, the stable metabolite of PGI2, Hemodynamic changes during CFRs. Table 3 shows the hemodynamic changes that occurred during CFRs with dazoxiben and saline treatment. There were no significant differences for any hemodynamic variable between the dazoxiben-treated and saline-treated groups. However, with time there were significant decreases in aortic systolic and diastolic pressures and in left ventricular dP/dt in the dazoxiben-treated animals.
Hemodynamic effects of dazoxiben. Dazoxiben did not produce hemodynamic changes in control animals without coronary constrictions. Figure 4 illustrates that dazoxiben, at doses of 1.0, 2.5, and 5.0 mg/kg, did not affect heart rate, arterial (systolic or diastolic) pressure, coronary blood flow, or left ventricular dP/dt, nor did it affect the transmural distribution of blood flow in five open-chest, anesthetized dogs.
Effects of dazoxiben on plasma aortic and distal coronary arterial TXB2 and 6-keto-PGFI, levels during intravascular platelet aggregation. Figure 5 shows the plasma TXB2 levels proximal (aortic) and distal to the coronary stenosis, before and during CFRs, and after the administration of dazoxiben. 126 pg/ml during CFRs. Aortic TXB2 levels also increased significantly during CFRs (73 ± 12 to 145 + 32 pg/ml). Abolition of the CFRs by dazoxiben was accompanied by a normalization of both aortic and distal coronary arterial TXB2 to control levels. The levels of 6-keto-PGF1, in distal coronary arterial blood also increased 259%, from control (preconstriction) levels of 133 ± 22 to 344 ± 41 pg/ml. In addition to decreasing TXB2 levels, dazoxiben left elevated PGI2 values (343 + 82 pg/ml) unaltered ( figure 5, B) . The ratio of 6-keto-PGF,, to TXB2 concentration, which is independent of flow rates from the distal coronary catheter at the three time points, is shown in figure 5 , D. The 6-keto-PGFI/TXB2 ratio declined from a control value of 3.04 ± .67 to 2.9 ± 0.9 with CFRs; this ratio increased significantly to 7.1 + 1.6 after dazoxiben administration. The increased ratio of 6-ketoPGFjTXB2 after dazoxiben was due to the reduction in the TXB2 concentration.
Morphologic observations. Periconstrictor segments of LAD obtained at the nadir of blood flow contained microthrombi primarily composed of masses of aggre- gated platelets ( figure 6 ). The arterial walls exhibited multiple foci of endothelial denudation and damage to the internal elastic lamella. Platelets and leukocytes (neutrophils) were frequently adherent to the vessel wall in these areas. The control vessels contained loosely arranged erythrocytes and a few other blood elements, but no aggregates of platelets were identified.
Effects of systemically administered dazoxiben on PG and TX production by platelets in vitro. Arachidonic acidinduced TXA2 and PGE2 production by platelet-rich plasma prepared from blood samples taken before and after administration of dazoxiben were measured in five dogs. Exogenously added arachidonic acid stimulated PGE2 and TXB2 production in platelet-rich plasma prepared from control (predazoxiben) blood samples (figure 7). TXB2 (but not PGE2) production was
Vol. 69, No. 6, June 1984 suppressed or eliminated in platelet-rich plasma isolated from blood samples taken 5 and 30 min after dazoxiben. Efects of dazoxiben on prostacyclin and PGE2 production by canine coronary arteries in vitro. Table 4 shows the effects of dazoxiben on endogenous PGE2 and PGI2
(measured as 6-keto-PGFia) production in vitro in canine coronary arterial rings. Dazoxiben did not alter the production of PGE2 or 6-keto-PGF,, significantly.
Discussion
The results of this study show that, in our experimental preparation, the TX-synthetase inhibitor dazoxiben abolishes or attenuates CFRs presumably produced by alternating formation and dislodgement of platelet-red blood cell thrombi.'2 These CFRs were accompanied by physiologically important changes in endocardial and epicardial blood flow. Thus, the ability to prevent CFRs would be expected to translate into an important preservation of blood flow and contractile function.
Morphologic examination of coronary arteries at the site of constriction revealed platelet thrombi with blood erythrocytic and leukocytic involvement. These 7 have demonstrated in the superfused cat coronary aitery that dazoxibin does not display many TXA2-receptor antagonist properties. Thus, there is little evidence to support the notion that antagonism of TXA2-induced coronary vasoconstriction plays an important role in this preparation. Also, the ability of systemically administered dazoxiben to inhibit arachidonatestimulated TXA2 (and not PGE2) production in platelets, coupled with the lack of effect on canine coronary arterial PGI2 synthesis in vitro, is strong evidence that dazoxiben selectively inhibited TXA2 production in the concentrations used in the present study. Recently, Schumacher and Lucchesi28 have reported that dazoxiben also reduces in vivo thrombotic activity. The role of coronary thrombosis as either a primary or secondary event in the pathogenesis of acute myocardial infarction is becoming increasingly recognized,29 and previous studies have suggested a potential role for thromboxane in perpetuating the syndrome of unstable angina pectoris in patients. 4 Folts et al.1' have demonstrated previously that aspirin diminishes the frequency of CFRs in this same experimental preparation, and a recent multicenter clinical trial conducted by the Veterans Administration has demonstrated that the equivalent of one aspirin per day reduces mortality and the frequency of myocardial infarction in patients with unstable angina pectoris.30 In-view of theeffectiveness of dazoxiben in abolishing existing cyclic coronary flow changes and associated increases in TXA2 production in this experimental preparation, this drug (and other similar TX-synthetase inhibitors) should provide relatively selective tools with which to explore the role of increases in TXA2 levels as well as alterations in the balance between TXA. and prostacyclin in initiating and/or perpetuating certain ischemic heart disease syndromes. The possible benefit of TX- synthetase inhibitors in treating selected patients with unstable angina pectoris needs to be determined.
